<DOC>
	<DOCNO>NCT02764619</DOCNO>
	<brief_summary>A randomized , double-blinded , placebo-controlled study evaluate effect spironolactone addition conventional treatment compare placebo patient paroxysmal persistent atrial fibrillation preserve leave ventricular ejection fraction T1 mapping , structure function leave atrium ventricle assess transthoracic echocardiography cardiac magnetic resonance ( CMR ) , number recurrent episodes atrial fibrillation biomarkers measure blood .</brief_summary>
	<brief_title>Inhibition Aldosterone Reduce Myocardial Diffuse Fibrosis Patients With Paroxysmal Persistent Atrial Fibrillation Preventing Recurrent Episodes Atrial Fibrillation</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) common sustain cardiac arrhythmia present 1 % population 60 year age reach 15 % 80 year . Due demographic change Danish population , incidence prevalence AF expect double within next 30 year . Furthermore number disease associate high prevalence AF ischemic heart disease , valvular heart disease , diabetes mellitus hypertension also expect increase prevalence due age population contribute increase incidence AF . AF increase mortality cause important morbidity , mainly due thromboembolic complication increase health economic cost . Additionally , AF associate reduce quality life . The onset maintenance AF highly complex frequent pathoanatomic change AF atrial fibrosis . In recent year , experimental clinical study demonstrate atrial remodelling dilation AF depend cellular hypertrophy , fibroblast proliferation tissue fibrosis . Atrial fibrosis lead disruption electrical side-to-side junction muscle bundle potentially arrhythmogenic mechanism . The association atrial fibrosis AF subject intense recent investigation , widely accept interstitial fibrosis create substrate arrhythmia . It believe atrial myocardial fibre bundle separate connective tissue , conduction property alter effect axial resistance , lead arrhythmia . Myocardial fibrosis precede grow activity extracellular matrix ( ECM ) , pro-inflammatory cytokine time pronounce collagen ( type I III ) expression . Histological study patient AF sick sinus syndrome show extensive fibrosis atrial muscle sinus node internodal tract . These result suggest myocardial interstitial fibrosis play crucial role AF . Recent research suggest many structural electrophysiological change lead AF attenuate reversed treatment Upstream Therapy target rennin-angiotensin II-aldosterone system ( RAAS ) . Upstream therapy angiotensin-converting enzyme inhibitor ( ACEIs ) , angiotensin II receptor blocker ( ARBs ) spironolactone posse antifibrotic property , addition , well-known mechanisms action . Most clinical trial data suggest RAAS inhibition ACEI ARB associate low risk incident AF patient heart failure , data hypertension trial inconsistent . Increased activation RAAS may key role development maintenance AF . Especially angiotensin II aldosterone draw attention . Aldosterone hypertensive action , induces hypertrophy fibrosis cardiomyocytes endothelium , modulate ion current refractoriness heart cycle . Arrhythmogenic aldosterone mechanism include inhibition noradrenalin reuptake , attenuation baroreceptor activity , increase sensitivity catecholamine reduce sinus rhythm variability . The expression aldosterone receptor angiotensin II receptor ( AT1 AT2 ) increase atria AF patient . For example , Boldt et al . report 100 % increase AT1 receptor density leave atrium patient chronic paroxysmal AF compare sinus rhythm . This reflect increased tissue activation angiotensin II fibrillating atrium . Moreover , multiple study demonstrate vicious cycle RAAS aldosterone enhance effect angiotensin II , part via increase transcription AT1 receptor , whereas angiotensin II increase systemic tissue level aldosterone . These finding consistent finding elevate plasma level angiotensin II aldosterone AF study Goette et al . By block mineralocorticoid receptor MRAs , RAAS over-activation diminish . Available data suggest direct effect spironolactone structural electrical property atria , prevent occurrence maintenance AF antifibrotic property , well indirect influence improve control heart failure hypertension , know risk factor AF . Dabrowski et al . document significant reduction ( p &lt; 0.0001 ) recurrence symptomatic AF episodes patient symptomatic paroxysmal AF treat spironolactone 25 mg/day compare patient treat enalapril beta-blocker . In addition , effect spironolactone prominent enalapril already 9-12 month treatment , effect enalapril less pronounced . Moreover , addition enalapril spironolactone influence frequency AF recurrence . New research acknowledge long-term treatment ACEI ARB reliably suppress RAAS long term , well-documented phenomenon know aldosterone escape . Aldosterone potentially important component RAAS , well investigate context AF prevention patient without heart failure . After period initial suppression , aldosterone concentration increase normal normal level . Spironolactone prevent aldosterone escape prohibit fibrosis effectively ACEI ARB . It show reduce mortality patient heart failure , data effect incidence atrial fibrillation still limit . Hypothesis : Spironolactone add optimal medical treatment reduce diffuse myocardial fibrosis , diminish atrial remodel improve function leave atrium ventricle , thus prevent recurrent episode AF decrease inflammatory biomarkers compare conventional treatment . Study design : This prospective , randomize , double-blinded , placebo-controlled , parallel group , single center , investigator-initiated study . The intervention group : spironolactone fix dose 25 mg per day . The control group : placebo . Patients group treat study medicine throughout 12 month additionally follow therapeutic recommendation accord Danish Society Cardiology guideline treatment AF . Comprehensive transthoracic echocardiography , 12-lead ECG , biomarkers Holter monitor perform time randomization 6 12 month , respectively . Blood sample ECG collect one week onset treatment , subsequently 1 , 2,3,6,9 12 month . During period 12 month , patient follow recurrence symptomatic AF . Any relapse symptomatic arrhythmia document , possible 12-lead ECG Holter monitoring . Only document AF-recurrence 12-lead ECG Holter monitoring take account . CMR exams preform baseline 12 month , respectively .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Patients ≥ 18 year age , male female . Paroxysmal persistent atrial fibrillation one occasion , detect 12lead ECG Holter monitor atrial fibrillation episode last ≥ 30 second within last 12 month prior screen visit . Women childbearing potency must use effective contraception ( e.g . implant , hormonal depot injection , combine oral contraceptive , intrauterine device vasectomize partner ) . Men enrol study must agree use adequate barrier birth control measure treatment period study . Reliable contraception maintain throughout study 30 day study drug discontinuation . Written inform consent sign studyspecific procedure . Permanent AF . Previous radiofrequency ablation / previous surgical therapy AF . Heart failure ( New York Heart Association [ NYHA ] ≥ II or/and leave ventricular ejection fraction [ LVEF ] le 40 % ) . Severe coronary artery disease ( acute coronary syndrome ( ACS ) within 6 month prior screen visit , previous coronary artery bypass graft [ CABG ] stabile angina pectoris classify Canadian Cardiovascular Society [ CCS ] ≥II ) . The definition ACS current European Society Cardiology ( ESC ) American College Cardiology ( ACC ) / American Heart Association ( AHA ) guideline . Stroke transient ischemic cerebral attack within 6 month prior screen visit . Pregnant woman , breastfeed woman woman childbearing potential adequate birth control . Presence severe hemodynamically significant valvular heart disease . Hepatic insufficiency classify ChildPugh B C . Any disease limit life expectancy le 1 year . Participation another clinical trial , either within last 30 day ongoing . Morbus Addison . Ongoing therapy class IC agent ( flecainide , propafenone ) amiodarone , dronedarone sotalol . Chronic kidney disease ( estimate glomerular filtration rate [ eGFR ] ≤ 45 ml/min/1,73 m2 [ MDRD ] ) . Intolerance contradiction spironolactone , i.e . late product resume Spirix® . Patients noncompliant treatment . Mental disorder suspect interact study outcome patient characteristic may interfere adherence study protocol , dementia , substance abuse . Any surgical medical condition opinion investigator would jeopardize evaluation efficacy safety . Baseline serum potassium ≥ 5,0 mmol/l serum sodium &lt; 135 mmol/l . Note : one reassessment electrolytes allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Upstream therapy , spironolactone</keyword>
	<keyword>Atrial remodelling</keyword>
	<keyword>Modified look-locker inversion recover ( MOLLI ) sequence</keyword>
	<keyword>T1 mapping</keyword>
	<keyword>Diffuse myocardial fibrosis</keyword>
</DOC>